0001104659-20-103494.txt : 20200909
0001104659-20-103494.hdr.sgml : 20200909
20200909170415
ACCESSION NUMBER: 0001104659-20-103494
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200904
FILED AS OF DATE: 20200909
DATE AS OF CHANGE: 20200909
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HEALY JAMES
CENTRAL INDEX KEY: 0001245624
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38958
FILM NUMBER: 201167062
MAIL ADDRESS:
STREET 1: 3000 SAND HILL ROAD, 4-250
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karuna Therapeutics, Inc.
CENTRAL INDEX KEY: 0001771917
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 270605902
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 33 ARCH STREET
STREET 2: SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
BUSINESS PHONE: 857-449-2244
MAIL ADDRESS:
STREET 1: 33 ARCH STREET
STREET 2: SUITE 3110
CITY: BOSTON
STATE: MA
ZIP: 02110
4
1
tm2030495d1_form4.xml
FORM 4
X0306
4
2020-09-04
0
0001771917
Karuna Therapeutics, Inc.
KRTX
0001245624
HEALY JAMES
SOFINNOVA INVESTMENTS, INC.,
3000 SAND HILL ROAD, 4-250
MENLO PARK
CA
94025
1
0
0
0
Common Stock
2020-09-04
4
P
0
1670
70.12
A
1887272
I
By Sofinnova Venture Partners X, L.P.
Common Stock
2020-09-04
4
P
0
45317
71.30
A
1932589
I
By Sofinnova Venture Partners X, L.P.
Common Stock
2020-09-04
4
P
0
6461
72.73
A
1939050
I
By Sofinnova Venture Partners X, L.P.
Common Stock
2020-09-04
4
P
0
8330
73.59
A
1947380
I
By Sofinnova Venture Partners X, L.P.
Common Stock
2020-09-08
4
P
0
504
73.00
A
1947884
I
By Sofinnova Venture Partners X, L.P.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $69.66 to $70.61, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (1) to this Form 4.
All shares held by Sofinnova Venture Partners X, L.P. ("SVP X"). Sofinnova Management X, L.L.C. ("SM X"), the general partner of SVP X, may be deemed to have sole voting power, and Dr. James I. Healy, Dr. Maha Katabi, and Dr. Michael F. Powell, the managing members of SM X, may be deemed to have shared power to vote these shares. Such individuals disclaim beneficial ownership of such shares except to the extent of their pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $70.66 to $71.50, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $72.30 to $73.27, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $73.30 to $74.00, inclusive. The reporting person undertakes to provide to Karuna Therapeutics, Inc., any security holder of Karuna Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote (5) to this Form 4.
/s/ Nathalie Auber, Attorney-in-Fact
2020-09-09